Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coya Therapeutics, Inc. filings document regulatory and financial disclosures for a clinical-stage biotechnology company developing Treg-enhancing biologics for neurodegenerative disorders. The record includes Form 8-K reports on operating results, corporate updates, clinical and regulatory disclosures for COYA 302, and study results involving low-dose IL-2 and CTLA4-Ig approaches in frontotemporal dementia.
Filings also cover material agreements and milestone payments under the company’s development and license relationship with Dr. Reddy’s Laboratories, board and executive-chairman changes, compensation and separation arrangements, and capital-structure disclosure for Coya’s Nasdaq-listed common stock. These documents provide formal disclosure of governance matters, collaboration economics, clinical-program status, and other material events.
Coya Therapeutics (COYA) priced an underwritten public offering. The company agreed to sell 4,181,818 shares of common stock, including 545,454 from the underwriter’s fully exercised option, at $5.50 per share. Gross proceeds are estimated at approximately $23.0 million before fees and expenses, with closing expected on or about October 27, 2025, subject to customary conditions.
The deal was conducted under an effective Form S-3, with Lucid Capital Markets as underwriter. Directors and executive officers entered lock-up agreements restricting sales through January 22, 2026. Allele Capital Partners, via Wilmington Capital Securities, acted as financial advisor; the company will pay $200,000 and issue warrants for 100,000 shares at a $5.50 exercise price under a private placement exemption.
Coya Therapeutics, Inc. launched a primary offering of 3,636,364 shares of common stock at $5.50 per share. Gross proceeds are $20,000,002, with underwriting discounts of $1,400,000 and estimated net proceeds of about $18.1 million after expenses.
The company granted the underwriter a 30‑day option to buy up to 545,454 additional shares. If fully exercised, total underwriting discounts would be $1.6 million and estimated net proceeds approximately $20.9 million. Lucid Capital Markets, LLC is the sole bookrunner.
Coya plans to use the proceeds for working capital and other general corporate purposes, including funding its clinical development plan, and estimates the financing, together with existing cash and equivalents, will fund operations into the second half of 2027. Shares outstanding were 16,742,638 as of October 21, 2025; a 90‑day lock‑up applies to the company and its directors and officers.
Coya Therapeutics, Inc. launched a preliminary prospectus supplement for an underwritten primary offering of common stock on Nasdaq under “COYA,” with Lucid Capital Markets, LLC as sole bookrunner. The filing includes a 30-day option for the underwriter to buy additional shares at the public offering price, less discounts and commissions. Proceeds will go to the company.
The company plans to use net proceeds for working capital and other general corporate purposes, including funding its clinical development plan. A 90-day lock-up applies to the company and to directors and executive officers. As context, shares outstanding were 16,742,638 as of October 21, 2025. The last reported sale price was $7.36 per share on October 22, 2025.
Coya Therapeutics, Inc. reports receiving a $4.2 million milestone payment from its strategic partner Dr. Reddy’s Laboratories. The payment was triggered when the FDA accepted Coya’s Investigational New Drug application for a planned Phase 2 clinical study of COYA 302 in amyotrophic lateral sclerosis (ALS).
Coya is also entitled to an additional $4.2 million from Dr. Reddy’s Laboratories when the first patient is dosed in this Phase 2 ALS study, which is designed as a randomized, double-blind, placebo-controlled, multi-center trial with an open-label extension.
Coya Therapeutics focuses on regulatory T cells (Tregs) and is developing low-dose IL-2 (LD IL-2) combination biologics for neurodegenerative disorders. The company describes COYA 302 as a "Pipeline in a Product" and reports nonclinical data showing COYA 303 increased Treg suppressive function by 42% (p < 0.001) versus single agents, and reduced BAX transcript levels (p < 0.01), supporting Treg survival. COYA 301 alone increased Treg suppression 15% and GLP-1RA alone 20% in the same assay. Coya re-submitted an IND on June 30, 2025 to support a planned Phase 2 randomized, double-blind, placebo-controlled 24-week study (with 24-week open-label extension) of COYA 302 in ALS and plans to initiate the study upon IND acceptance. The company reported net losses of $13.4 million and $7.9 million for the six months ended June 30, 2025 and 2024, respectively, and an accumulated deficit of $54.1 million as of June 30, 2025.
Dov A. Goldstein, a director of Coya Therapeutics, acquired 17,557 shares of the company's common stock on 08/18/2025 at a price of $1.09 per share, increasing his reported beneficial ownership to 27,557 shares. The Form 4 shows a simultaneous derivative transaction: 17,557 stock options with a $1.09 exercise price were exercised on the same date; those options were fully vested and had an original exercisability date of 04/01/2021 and an expiration date of 03/30/2031. The filing was submitted by an attorney-in-fact on 08/19/2025.
Coya Therapeutics is offering securities on a shelf registration for up to $75,000,000 to sell common stock, preferred stock, warrants, debt securities, subscription rights and units from time to time. The company is clinical-stage, focused on therapies that enhance regulatory T cells (Tregs), with lead asset COYA 302 (a combination of low-dose IL-2 and CTLA4-Ig) and an autologous Treg program that completed Phase 1 and Phase 2a studies in ALS.
Pipeline expansion includes COYA 303, a LD IL-2 plus GLP-1RA combination. A published preclinical study reported COYA 303 increased Treg suppressive function by 42% (p < 0.001) versus single agents (15% and 20%), and reduced BAX transcripts (p < 0.01), suggesting enhanced Treg survival. The company resubmitted an IND for the planned COYA 302 Phase 2 ALS study and the FDA has delayed its initial review, indicating a decision expected no later than August 29, 2025.
Financially, Coya reported net losses of $13.4 million for the six months ended June 30, 2025, an accumulated deficit of $54.1 million, and had 16,725,081 common shares outstanding; the last reported Nasdaq sale price was $6.15 per share. The company qualifies as an emerging growth company and elected the extended transition for new accounting standards.
Coya Therapeutics held $29.8 million in cash and cash equivalents as of June 30, 2025 and reported an accumulated deficit of $54.1 million. The company recorded a net loss of $6.09 million for the three months and $13.40 million for the six months ended June 30, 2025. Collaboration revenue declined to $163,616 for the quarter and $421,500 for the six months, versus substantially higher amounts in the prior-year periods driven by upfront license recognition in 2024.
The balance sheet shows $1.372 million in deferred collaboration revenue. Under the DRL Development Agreement the company received a prior upfront payment of $7.5 million and $3.9 million in a June 2024 amendment; remaining R&D services revenue is being recognized over time. The company resubmitted an IND for COYA 302 on June 30, 2025 and disclosed the FDA told the company it cannot meet the initial review goal date but expects to provide a decision no later than August 29, 2025. Management states existing cash should fund operations for at least one year after issuance of these financial statements, and that substantial additional financing will be required thereafter.
Coya Therapeutics, Inc. filed a current report to note that it issued a press release with information about its results of operations for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the Exchange Act.